In-Cheol Choi
Corporate Officer/Principal en KOREA UNITED PHARM INC. .
Fortuna: 60 164 $ al 31/05/2024
Origen de la red de primer grado In-Cheol Choi.
| Entidad | Tipo de entidad | Industria | |
|---|---|---|---|
| Public Company | Pharmaceuticals: Major | 11 |
Gráfico Empresas conectadas de segundo grado
Relaciones con varias empresas
Empresas conectadas a In-Cheol Choi a través de su red personal
| Empresa | Sector | Personas relacionadas | Puesto principal |
|---|---|---|---|
| Yonsei University | College/University | Graduate Degree | |
| Seoul National University | College/University | Corporate Officer/Principal | |
| Wonkwang University | College/University | Undergraduate Degree | |
| Hankuk University of Foreign Studies | College/University | Undergraduate Degree | |
Samhwa Flour Mills Co. Ltd.
 Samhwa Flour Mills Co. Ltd. Electric UtilitiesUtilities Samhwa Flour Mills Co. Ltd. was founded in 1957. The South Korean company engages in the generation, transmission and distribution of electric energy for sale. The CEO is Jeong-Tae Ju. | Electric Utilities | Chief Executive Officer | |
| Chung-Ang University | College/University | Doctorate Degree Graduate Degree Graduate Degree Doctorate Degree | |
| Kangwon National University | College/University | Doctorate Degree | |
Kyung Hee University
 Kyung Hee University Other Consumer ServicesConsumer Services Kyung Hee University provides academic courses and grants academic degrees. It has udergraduate, graduate, international student, and international faculty programs. The firm also provides scholarships and operates Kyung Hee Medical Center, Kyung Hee University Hospital at Gangdong, and Kangnam Korean Hospital. The company was founded on February 15, 1949 and is headquartered in Seoul, South Korea. | College/University | Doctorate Degree | |
| United Douglas Pharm, Inc | Chief Executive Officer | ||
Pelemed Co., Ltd.
 Pelemed Co., Ltd. Pharmaceuticals: GenericHealth Technology Pelemed Co., Ltd. is a South Korean company based in Seoul that specializes in the development of innovative anticancer drugs. Pelemed's technology platform, PeLeSeLect & AHEDD, overcomes mutation-mediated drug resistance and enables precision drug design for kinase-targeted therapies. The company's pipeline includes several drugs in various stages of development for the treatment of different types of cancer. Pelemed has received funding from the IP Voucher Funded by MSS and has a scientific advisory board that includes experts from the ASAN Medical Center Bio Core Facility. The company was founded in 2019, and its CEOs are Yong-Chul Kim and Soo-Yeon Jang. | Pharmaceuticals: Generic | Director/Board Member |
Estadísticas
Internacional
| Corea del Sur | 10 |
| Estados Unidos | 2 |
Sectorial
| Consumer Services | 8 |
| Utilities | 2 |
| Health Technology | 2 |
Operativa
| Director/Board Member | 9 |
| Corporate Officer/Principal | 7 |
| Chief Executive Officer | 4 |
| Doctorate Degree | 4 |
| Independent Dir/Board Member | 4 |
Las relaciones más conectadas
| Insiders | |
|---|---|
| Duk-Young Kang | 4 |
| Gun-Wook Kang | 3 |
| Gui-Ja Kim | 2 |
| Jin-Ho Cho | 2 |
| Yong-Woo Cho | 2 |
| Won-Ho Kang | 2 |
| Hyung-Rae Kim | 2 |
| Won-Tae Jeong | 2 |
| Yeon-Woong Choi | 2 |
| Jeong-Tae Ju | 2 |
| Won-Il Kal | 1 |
- Bolsa de valores
- Insiders
- In-Cheol Choi
- Conexiones Empresas
